ANAPTYSBIO, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
ANAPTYSBIO, INC. (ANAB) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 628 shares for the 6-month period ending 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-09-21
- ANAPTYSBIO, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 8.40M shares, a 0.67% increase year-over-year.
- ANAPTYSBIO, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 6.78M shares, a 3.75% decline year-over-year.
- ANAPTYSBIO, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 8.47M shares, a 32.48% increase year-over-year.
- ANAPTYSBIO, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 8.35M shares, a 17.92% increase year-over-year.
- ANAPTYSBIO, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 4.99K shares, a 4.02% decline from fiscal 2024.
- ANAPTYSBIO, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 5.19K shares, a 99.89% decline from fiscal 2023.
- ANAPTYSBIO, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 4.80M shares, a 20.69% increase from fiscal 2022.
- ANAPTYSBIO, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 3.98M shares, a 9.53% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 628.00 shares 10-KT · filed 2026-09-21 | ||||
| 2026-03-31 | 8.40M shares 10-Q · filed 2026-05-12 | ||||
| 2025-12-31 | 4.99K shares 10-KT · filed 2026-09-21 | 8.70M shares 10-K · filed 2026-03-03 | |||
| 2025-09-30 | 6.78M shares 10-Q · filed 2025-11-04 | 8.60M shares 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | 8.47M shares 10-Q · filed 2025-08-06 | 8.52M shares 10-Q · filed 2025-08-06 | |||
| 2025-03-31 | 8.35M shares 10-Q · filed 2026-05-12 | ||||
| 2024-12-31 | 5.19K shares 10-KT · filed 2026-09-21 | 6.92M shares 10-K · filed 2025-02-27 | |||
| 2024-09-30 | 7.04M shares 10-Q · filed 2025-11-04 | 6.91M shares 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | 6.40M shares 10-Q · filed 2025-08-06 | 6.77M shares 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | 7.08M shares 10-Q · filed 2025-05-05 | ||||
| 2023-12-31 | 4.80M shares 10-K · filed 2026-03-03 | ||||
| 2023-09-30 | 4.60M shares 10-Q · filed 2024-11-05 | 4.78M shares 10-Q · filed 2024-11-05 | |||
| 2023-06-30 | 4.75M shares 10-Q · filed 2024-08-05 | 4.87M shares 10-Q · filed 2024-08-05 | |||
| 2023-03-31 | 4.98M shares 10-Q · filed 2024-05-09 | ||||
| 2022-12-31 | 3.98M shares 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | 3.87M shares 10-Q · filed 2023-11-02 | 3.95M shares 10-Q · filed 2023-11-02 | |||
| 2022-06-30 | 3.90M shares 10-Q · filed 2023-08-07 | 3.98M shares 10-Q · filed 2023-08-07 | |||
| 2022-03-31 | 4.00M shares 10-Q · filed 2023-05-11 | ||||
| 2021-12-31 | 3.63M shares 10-K · filed 2024-03-11 | ||||
| 2020-12-31 | 2.90M shares 10-K · filed 2023-03-01 | ||||
| 2019-12-31 | 2.46M shares 10-K · filed 2020-03-02 | ||||
| 2019-09-30 | 2.47M shares 10-Q · filed 2019-11-08 | 2.45M shares 10-Q · filed 2019-11-08 | |||
| 2019-06-30 | 2.52M shares 10-Q · filed 2019-08-08 | 2.44M shares 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | 2.36M shares 10-Q · filed 2019-05-07 | ||||
| 2018-12-31 | 2.45M shares 10-K · filed 2020-03-02 | ||||
| 2018-09-30 | 2.40M shares 10-Q · filed 2019-11-08 | 2.52M shares 10-Q · filed 2019-11-08 | |||
| 2018-06-30 | 2.54M shares 10-Q · filed 2019-08-08 | 2.58M shares 10-Q · filed 2019-08-08 | |||
| 2018-03-31 | 2.61M shares 10-Q · filed 2019-05-07 | ||||
| 2017-12-31 | 2.64M shares 10-K · filed 2019-02-28 | ||||
| 2017-09-30 | 1.75M shares 10-Q · filed 2018-11-08 | 2.09M shares 10-Q · filed 2018-11-08 | |||
| 2017-06-30 | 2.11M shares 10-Q · filed 2018-08-07 | 2.22M shares 10-Q · filed 2018-08-07 | |||
| 2017-03-31 | 2.33M shares 10-Q · filed 2018-05-08 | ||||
| 2016-12-31 | 2.64M shares 10-K · filed 2020-03-02 | 13.90M shares 10-K · filed 2018-03-05 | |||
| 2016-09-30 | 922.00K shares 10-Q · filed 2017-11-07 | 1.02M shares 10-Q · filed 2017-11-07 | |||
| 2016-06-30 | 981.00K shares 10-Q · filed 2017-08-10 | 973.00K shares 10-Q · filed 2017-08-10 | |||
| 2016-03-31 | 13.96M shares 10-Q · filed 2017-05-12 | ||||
| 2015-12-31 | 10.50M shares 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |